Home / Leaderboard / TCG Crossover Management, LLC
TCG Crossover Management, LLC
Chen Yu · Venture Capital · Growth
TCG Crossover Management, LLC (also known as TCG X) is a specialized investment firm focused on the life sciences and healthcare sectors. Founded in 2020 by Dr. Chen Yu, formerly a Managing Partner at Vivo Capital, the firm was established in partnership with The Column Group to bridge the gap between private and public healthcare investments. Headquartered in Palo Alto, California, TCG Crossover invests in innovative drug discovery and biotechnology companies that address significant unmet medical needs. The firm manages multiple funds and leverages a deep network of science partners to perform rigorous technical diligence, supporting portfolio companies from early-stage development through their transition into the public markets. By providing long-term capital and strategic expertise, TCG Crossover aims to advance disruptive medicines and improve patient outcomes globally.
Simulated Performance
| Metric | Value |
|---|---|
| Total return | +109.6% |
| YTD return | +31.3% |
| Sharpe ratio | 3.59 |
| Win rate | 58% |
| AUM | $3.6B |
| Inception | Oct 1, 2025 |
| Updated | Aug 20, 2026 |
Institution Status
| Field | Value |
|---|---|
| AUM | $3.6B |
| Turnover | Low (<15%) |
| Avg holding | 18 Months |
| Inception | Oct 1, 2025 |
| Website | https://www.tcgcrossover.com/ |
Current Holdings
Updated on Aug 20, 2026.
| Ticker | Name | Portfolio % | Return |
|---|---|---|---|
| ABVX | Abivax SA American Depositary Shares | 23.9% | +8.1% |
| TNGX | Tango Therapeutics Inc | 8.8% | +16.0% |
| CGON | CG Oncology, Inc. Common stock | 7.6% | +47.0% |
| COGT | Cogent Biosciences Inc | 5.9% | +50.3% |
| SYRE | Spyre Therapeutics Inc. | 5.5% | +75.2% |
| DNTH | Dianthus Therapeutics Inc. | 5.1% | +72.8% |
| IMVT | Immunovant Inc | 4.9% | +31.6% |
| AMLX | Amylyx Pharmaceuticals Inc | 4.0% | +151.9% |
| ZLAB | Zai Lab Ltd | 4.0% | +29.1% |
| VOR | Vor Biopharma Inc | 3.7% | +44.8% |
| DYN | Dyne Therapeutics Inc | 3.3% | +63.5% |
| RVMD | Revolution Medicines Inc | 3.2% | +33.8% |
| MIRM | Mirum Pharmaceuticals Inc | 2.9% | -5.6% |
| BCRX | BioCryst Pharmaceuticals Inc | 2.9% | +10.7% |
| IRON | Disc Medicine Inc. | 2.9% | +14.7% |
| LBRX | LB Pharmaceuticals Inc Common Stock | 2.5% | +17.6% |
| TYRA | Tyra Biosciences Inc | 2.4% | +10.1% |
| RLAY | Relay Therapeutics Inc | 2.3% | +32.6% |
| AURA | Aura Biosciences Inc | 2.1% | -2.8% |
| GLUE | Monte Rosa Therapeutics Inc | 2.1% | +13.7% |
Recent activity
| Date | Action | Ticker | Weight |
|---|---|---|---|
| Aug 10, 2026 | BUY | LBRX | 2.2% → 2.5% |
| Aug 10, 2026 | SELL | GLUE | 2.2% → 2.1% |
| Aug 10, 2026 | BUY | AMLX | 3.6% → 4.0% |
| Aug 10, 2026 | SELL | DYN | 3.4% → 3.3% |
| Aug 10, 2026 | BUY | ZLAB | 3.2% → 4.0% |
Investment Style Analysis
TCG Crossover Management, LLC is widely recognized for employing a Growth strategy. As of Aug 20, 2026, the firm oversees approximately $3.6B in assets under management (AUM). The portfolio demonstrates a clear preference for the Biotechnology and Drug Manufacturers - Specialty & Generic sectors, reflecting a high-conviction approach to capital allocation.
Recent Market Moves
During the latest rebalancing period ending Aug 10, TCG Crossover Management, LLC made a significant move by increasing exposure to LBRX. This adjustment aligns with the fund's dynamic approach to risk management and capital deployment in current market conditions.
Investment Philosophy
TCG Crossover employs a science-driven investment philosophy centered on identifying and backing companies with the potential to develop transformative therapeutics. The firm utilizes a 'crossover' strategy, investing in both high-growth private companies and publicly traded entities within the biopharmaceutical space. Their approach is characterized by deep involvement with management teams and a reliance on an extensive network of scientific advisors to evaluate clinical data, regulatory pathways, and market potential. By focusing on disruptive innovation and biological validation, TCG Crossover seeks to provide the necessary capital and strategic guidance to help healthcare companies achieve significant clinical milestones and commercial success.
Disclaimer
The content provided on this page, including the simulated portfolio performance, holdings analysis, and AI-generated insights, is for informational and educational purposes only. It does not constitute financial advice, investment recommendations, or an offer to buy or sell any securities. All data is derived from historical SEC 13F filings and other public disclosures, which have a reporting lag. The "Simulated Performance" is a hypothetical reconstruction based on past disclosures and does not represent the actual returns of the institution. Past performance is not indicative of future results. Tritonix.ai is not affiliated with TCG Crossover Management, LLC.
Similar Investment Style
Based on Growth.
- Jaunty Global Limited — Alvin Jiang · 3M +31.1%
- Oberweis Asset Management, Inc. — James W. Oberweis · 3M -12.6%
- Needham Investment Management, LLC — George A. Needham · 3M -23.8%
- Hartline Investment Corporation — Brian W. Hart · 3M +1.9%
Frequently asked questions
How is the simulated portfolio for TCG Crossover Management, LLC constructed?
This simulation is powered by Tritonix AI using official SEC filings. We focus on the "Best Ideas" by filtering for only the Top 20 largest holdings and rebalancing them to 100%. The simulation tracks performance starting from Oct 1, 2025. Our AI monitors for updates every Monday to capture major shifts. This concentrated approach highlights the manager's true stock-picking skill and mirrors their actual investment returns.
What is TCG Crossover Management, LLC's largest holding?
As of the latest filing, TCG Crossover Management, LLC's top position is Abivax SA American Depositary Shares (ABVX), representing 23.9% of the portfolio. This reflects a high-conviction bet by the institution.
What is TCG Crossover Management, LLC's historical performance and risk profile?
Our simulation indicates a total return of +109.6% with a win rate of 58%. Notably, the portfolio maintains a Sharpe Ratio of 3.59, suggesting an exceptional level of risk-adjusted returns compared to the broader market.
What sectors does TCG Crossover Management, LLC primarily invest in?
TCG Crossover Management, LLC has a strong preference for the Biotechnology sector, which makes up 97.1% of their disclosed assets. The portfolio also has exposure to Drug Manufacturers - Specialty & Generic, indicating a specific thematic focus.
Is TCG Crossover Management, LLC's portfolio concentrated or diversified?
TCG Crossover Management, LLC runs a moderately concentrated portfolio with 20 disclosed positions. The top 3 holdings alone account for 40.4% of the total portfolio weight, suggesting a strategy that favors broader market exposure.
How has TCG Crossover Management, LLC performed in 2026?
Our AI-simulated model portfolio for TCG Crossover Management, LLC tracks a Year-to-Date (YTD) return of +31.3%. This metric helps investors gauge the institution's effectiveness in the current market environment.
Does Chen Yu manage TCG Crossover Management, LLC directly?
Yes, Chen Yu serves as the key portfolio manager for TCG Crossover Management, LLC, overseeing the investment strategy and final capital allocation decisions.